Magnetic Resonance Imaging Characterization of Chronic Pathologic Changes in a Swine Model of Central Venous Thrombosis: PC210.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Vascular Surgery"
DOI: 10.1016/j.jvs.2018.03.349
Abstract: Author Disclosures: C. Z. Abraham: Nothing to disclose; E. Jung: Nothing to disclose; J. Kaufman: Bio2 Medical: Consulting fees (eg, advisory boards), Ownership Interest, Cook Medical: Consulting fees (eg, advisory boards), Novate Medical: Consulting fees… read more here.
Keywords: advisory boards; nothing; nothing disclose; fees advisory ... See more keywords
P05 Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.70
Abstract: Introduction/Background Although well-tolerated, trastuzumab can lead to severe heart failure in 2–4% of patients. In the phase 3 LILAC trial, trastuzumab biosimilar ABP 980 demonstrated similar efficacy, safety, and immunogenicity to trastuzumab reference product (RP)… read more here.
Keywords: cardiac safety; amgen; safety; abp 980 ... See more keywords
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2017.23.3-b.s3
Abstract: DISCLOSURES Maher has received grants, consulting fees, and speaker fees from GlaxoSmithKline and UCB and grants from Novartis. He has also received consulting fees and speaker fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla,… read more here.
Keywords: idiopathic pulmonary; boehringer ingelheim; pulmonary fibrosis; survival idiopathic ... See more keywords